WenBo Guo

1 clinical trials · Sponsor

Record	Firm	Date
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy (NCT05811481)	WenBo Guo	2022-12-27

Every clearance here is in the API, with alerts when new ones post.